But there are no efficacy data, and the mechanism has a mountain to climb.
ApexOnco Front Page
Recent articles
CRB-601 and PF-06940434 fall by the wayside.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
The group’s on/off KRAS G12C inhibitor looks good, though patient numbers are small.
Four months after yielding first-in-human data INCA33890 enters phase 3.
But Tevimbra’s role looks shaky as adverse events loom.
JP Morgan approaches.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
